AbbVie wins conditional European nod for acquiring Allergan

"Our decision makes sure that the merger between AbbVie and Allergan will not disrupt the development of a promising innovative treatment for these diseases," Margrethe Vestager, the commissioner in charge of competition, said in a statement.

New Delhi: The European Commission said on Friday it had approved U.S. drugmaker AbbVie's planned $63 billion acquisition of the Botox-maker Allergan, subject to conditions.

The Commission, which oversees competition policy in the European Union, said its approval was conditional on the divestment of a product under development by Allergan to treat inflammatory bowel diseases.

"Our decision makes sure that the merger between AbbVie and Allergan will not disrupt the development of a promising innovative treatment for these diseases," Margrethe Vestager, the commissioner in charge of competition, said in a statement.

Also Read: Investigate, block AbbVie, Allergan USD 63 billion merger: Consumer Groups to Trade Commission

The Commission had found that Allergan's brazikumab was likely to compete with AbbVie's risankizumab, but the merger would have led to research into brazikumab to be halted, "preventing a promising drug from reaching the market".

To address the commission's concerns AbbVie has agreed to sell brazikumab to an investor that would continue its development.

AbbVie announced its plans to acquire Allergan in June to give it control of lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment loses U.S. patent protection.

Also Read: UCB psoriasis drug Bimekizumab beats AbbVie blockbuster Humira in late-stage trial